These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28103645)

  • 1. Prognostic Impact of Lymphocyte Subpopulations in Peripheral Blood after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies.
    Park SH; Park CJ; Park BG; Bae MH; Kim BH; Cho YU; Jang S; Park AJ; Kim DY; Lee JH; Lee JH; Lee KH
    Cytometry B Clin Cytom; 2018 Mar; 94(2):270-280. PubMed ID: 28103645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
    Park BG; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH
    Leuk Res; 2015 Dec; 39(12):1334-41. PubMed ID: 26422556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
    Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
    Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
    Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
    Dunbar EM; Buzzeo MP; Levine JB; Schold JD; Meier-Kriesche HU; Reddy V
    Haematologica; 2008 Dec; 93(12):1852-8. PubMed ID: 18945751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.
    Rogatko-Koroś M; Mika-Witkowska R; Bogunia-Kubik K; Wysoczańska B; Jaskuła E; Kościńska K; Nestorowicz K; Dziopa J; Szlendak U; Gwozdowicz S; Graczyk-Pol E; Lange A; Nowak J
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):63-71. PubMed ID: 27933342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
    Gärtner F; Hieke S; Finke J; Bertz H
    Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Lymphocyte Subsets of Grafts on the Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation.
    Jiang P; Yu F; Xu X; Cai Y; Yang J; Tong Y; Huang C; Qiu H; Zhou K; Zhang Y; Niu J; Shen C; Xia X; Wei Y; Shao J; Gao L; Song X; Wan L
    Cell Transplant; 2023; 32():9636897231157054. PubMed ID: 36905323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early immune reconstitution after hematopoietic stem cell transplantation].
    Zhu MX; Wan WL; Li HS; Wang J; Wang YF; Hu K; Ke XY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):515-22. PubMed ID: 27318917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation.
    Busca A; Lovisone E; Aliberti S; Locatelli F; Serra A; Scaravaglio P; Omedè P; Rossi G; Cirillo D; Barbui A; Ghisetti V; Dall'Omo AM; Falda M
    Hematology; 2003 Oct; 8(5):303-11. PubMed ID: 14530172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
    Xiong Y; Bensoussan D; Decot V
    Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation.
    Puissant-Lubrano B; Huynh A; Attal M; Blancher A
    Immunobiology; 2014 Aug; 219(8):611-8. PubMed ID: 24721705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Single center comparative analysis of hematopoietic cell transplantation from alternated donor in patients with hematologic malignancies].
    Wang J; Zhou J; Zheng HF; Wang PF; Fu CC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):159-65. PubMed ID: 25687066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.
    Servais S; Lengline E; Porcher R; Carmagnat M; Peffault de Latour R; Robin M; Sicre de Fontebrune F; Clave E; Maki G; Granier C; Xhaard A; Dhedin N; Molina JM; Toubert A; Moins-Teisserenc H; Socie G
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):507-17. PubMed ID: 24406505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.